A Look At Sotera Health (SHC) Valuation After Q1 2026 Results And CEO Transition

Simply Wall St.05-11

Sotera Health (SHC) just delivered a busy first quarter, pairing 10% year-over-year revenue growth and a move back to profitability with reaffirmed 2026 guidance and a planned CEO transition. See our ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2634424401?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-05-11 06:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634424401","market":"us","top_or_hot":-1,"title":"A Look At Sotera Health (SHC) Valuation After Q1 2026 Results And CEO Transition","media":"Simply Wall St.","content":"<div>\n<p>Sotera Health (SHC) just delivered a busy first quarter, pairing 10% year-over-year revenue growth and a move back to profitability with reaffirmed 2026 guidance and a planned CEO transition. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/a-look-at-sotera-health-shc-valuation-after-q1-2026-results\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Sotera Health (SHC) Valuation After Q1 2026 Results And CEO Transition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Sotera Health (SHC) Valuation After Q1 2026 Results And CEO Transition\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-11 06:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/a-look-at-sotera-health-shc-valuation-after-q1-2026-results><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sotera Health (SHC) just delivered a busy first quarter, pairing 10% year-over-year revenue growth and a move back to profitability with reaffirmed 2026 guidance and a planned CEO transition. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/a-look-at-sotera-health-shc-valuation-after-q1-2026-results\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/a-look-at-sotera-health-shc-valuation-after-q1-2026-results","article_id":"2634424401","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/a-look-at-sotera-health-shc-valuation-after-q1-2026-results","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2634424401","pubTimestamp":1778451662,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sotera Health (SHC) just delivered a busy first quarter, pairing 10% year-over-year revenue growth and a move back to profitability with reaffirmed 2026 guidance and a planned CEO transition.\nSee our latest analysis for Sotera Health.\nThe share price is US$15.67 after a 7.04% 1 month share price return. However, the 90 day share price return of 11.72% and year to date share price return of 11.42% suggest recent momentum has cooled. Even so, the 1 year total shareholder return of 18.44% and 3...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","SHC":"Sotera Health Company","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"2026年第一季度业绩和首席执行官换届后Sotera Health(SHC)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SHC":1.5},"content_text":"Sotera Health (SHC) just delivered a busy first quarter, pairing 10% year-over-year revenue growth and a move back to profitability with reaffirmed 2026 guidance and a planned CEO transition. See our latest analysis for Sotera Health. The share price is US$15.67 after a 7.04% 1 month share price return. However, the 90 day share price return of 11.72% and year to date share price return of 11.42% suggest recent momentum has cooled. Even so, the 1 year total shareholder return of 18.44% and 3 year total shareholder return of 6.09% contrast with a 5 year total shareholder return of 27.45%. This highlights that recent earnings beats, reaffirmed 2026 guidance and the incoming CEO are being weighed against longer term legal and leverage risks. If Sotera’s Q1 beat has you thinking about other healthcare names tied to medical technology and services, it could be a good moment to scan 35 healthcare AI stocks With SHC trading at US$15.67 alongside an indicated intrinsic discount and a sizeable gap to analyst targets, the key question is whether investors are overlooking earnings momentum and the incoming CEO, or whether the stock already reflects future growth. AdvertisementMost Popular Narrative: 23.6% Undervalued With Sotera Health trading at $15.67 against a narrative fair value of $20.50, the market price currently sits well below that framework.  The analysts have a consensus price target of $20.5 for Sotera Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $24.0, and the most bearish reporting a price target of just $16.0.  Read the complete narrative. Curious what kind of earnings ramp, margin shift and valuation multiple are built into that target, and how tightly analysts cluster around those assumptions. Result: Fair Value of $20.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to weigh ongoing EtO litigation and compliance costs, as well as elevated CapEx plans through 2027, which could pressure margins and limit financial flexibility. Find out about the key risks to this Sotera Health narrative. Another Way to Look at the Price The earlier narrative points to Sotera Health trading below an estimated fair value of $20.50, but the P/E ratio of 37.9x tells a different story. It sits slightly above the global Life Sciences average of 37.1x and well above the fair ratio of 22.4x, suggesting less margin for error if earnings or sentiment slip. Which lens do you trust more when the signals do not fully line up? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:SHC P/E Ratio as at May 2026Next Steps With mixed signals on valuation and sentiment running both hot and cold, it makes sense to look at the underlying data directly and decide quickly where you stand. To weigh the upside potential against the issues that are worrying investors, review the 4 key rewards and 2 important warning signs Looking for more investment ideas? If you stop with a single stock, you risk missing other opportunities that fit your style. Use the screener to line up your next few candidates.  Target quality at a discount by scanning 51 high quality undervalued stocks that pair solid fundamentals with room for a rerating. Prioritize resilience and focus on 71 resilient stocks with low risk scores that historically show fewer red flags. Spot potential future leaders early by reviewing the screener containing 23 high quality undiscovered gems before they get crowded.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634424401","isCrawlerRequest":true}